Amgen Calls For Halt To Neulasta Biosimilar Marketing
Amgen Inc. asked a Florida federal court Friday to stop Canadian generics maker Apotex Inc. from marketing its biosimilar copy of the blockbuster biologic Neulasta until it complies with a federal...To view the full article, register now.
Already a subscriber? Click here to view full article